Purpose/Objective: High-dose thoracic radiation therapy can cause significant adverse effects. Therefore, radical radiotherapy has historically been reserved for patients with stage I-III disease nonsmall cell lung cancer (NSCLC), and the most common indication for radiation therapy to the primary site for patients with metastatic (stage IV) NSCLC has been palliation for pain or other symptoms directly resulting from tumor. However, stage IV NSCLC contains a broad spectrum of patients, and prior studies have suggested that select patients with stage IV disease with a limited number of distant metastases ('oligometastasis') may benefit from radical therapy. We investigated prognostic factors associated with survival in patients with NSCLC and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis. Materials and Methods: From January 2000 through June 2011, 78 consecutive patients with oligometastatic NSCLC (<5 metastases) at diagnosis without prior thoracic surgery or radiation therapy, no prior or concurrent other malignancy and who underwent aggressive radio(chemo)therapy (≥45 Gy) to the primary site were assessed. Forty-four of these patients also received definitive local treatment for the oligometastases. Pulmonary and esophageal acute toxicity was scored according to the Common Terminology Criteria for Adverse Events version 3.0. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors were identified by univariate and multivariate analyses. Results: The median follow-up time for patients alive at the time of analysis was 35 months (range, 2-109). Rates of grade 2 radiation pneumonitis and esophagitis were 16.7% and 39.7%. Rates of severe (grade ≥3) pulmonary and esophageal toxicity were 6.4% and 19.4%. The locoregional relapse rate was 22% (17 patients, with 10 experiencing recurrence inside the radiation field), and 50 of the original 78 patients had new sites of distant metastases. For all patients, the 1-, 2-, and 3-year overall survival (OS) rates were 62%, 32%, and 25%, respectively. Univariate Cox proportional hazard analysis revealed better OS for those patients who received at least 63 Gy of radiation to the primary site (P=0.002), received definitive local treatment for oligometastasis (P=0.041), had a Karnofsky performance status (KPS) score >80 (P=0.007), had a gross tumor volume ≤124 cm3 (P=0.002), had adenocarcinoma histology (P=0.002), or had no history of respiratory disease (P=0.016). On multivariate analysis, radiation dose, performance status, and tumor volume retained significance (P=0.004, P=0.006, and P<0.001, respectively). Conclusions: Tumor volume, KPS, and receipt of at least 63 Gy to the primary tumor are associated with improved OS in patients with oligometastatic NSCLC at diagnosis. Our results suggest that a subset of such patients may benefit from aggressive local therapy. Purpose/Objective: Concurrent chemoradiation has improved the local control and survival for NSCLC patients at the cost of a higher incidence of side-effect, such as acute esophagus toxicity (AET). However the incidence and cause of late esophagus toxicity (LET) has not been thoroughly studied. Severe LET includes esophagus stenosis, perforation or fistulae, which may seriously affect the patients' quality of life or even lead to death. Purpose/Objective: Dyspnea is a very important and dose-limiting side-effect of radiotherapy (RT) of non-small cell lung cancer (NSCLC). Dyspnea is measured qualitatively on a zero-to-five scale according to the Common Toxicity Criteria system. Apart from lung damage, it is known that a decrease of cardiac output is a major cause of dyspnea. We therefore hypothesized that the amount of radiation dose delivered to the left ventricle of the heart is related to posttreatment development of dyspnea. Materials and Methods: A cohort of 78 NSCLC patients has been retrospectively obtained in Center 1. All patients have been treated between 2008 and 2009 with IMRT with individualised iso-toxic accelerated radiotherapy. CT, PETSUV and dosimetric 3D images are available per each patient. For all patients dyspnea scores before (baseline) and after RT are available. The aim of the present study was to predict the difference between maximal dyspnea score within 9 months after RT and baseline score. The left ventricle was defined according to PET-CT. An external dataset of 30 patients from Center 2 in another country was obtained.
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Results:
1: Overlap between the left ventricle and high radiation dose levels, adjusted for the mean heart dose ( Figure 1, upper panel) . Patients from both centers were pooled and we divided in two groups -those with improved dyspnea scores after RT (16%) and those who worsened S202 ESTRO 31 or stayed the same (84%). Visual inspection reveals a very high separation between the two groups, with only a few outliers. A formal statistical logistic-regression model produced an area under the curve (AUC) estimate of 0.82. 2: Relationship between heart volume and the overlap of high radiation dose and the left ventricle (Figure 1, lower panel) . This revealed that smaller heart volumes (as well as smaller PETSUV-dose overlap) are less susceptible to post-radiation dyspnea. We note that heart volume and mean heart dose are slightly positively related (correlation of 0.11). Our findings were confirmed on the external validation dataset.
Conclusions: Post-radiation dyspnea is associated with the radiation dose to the left ventricle of the heart. This should be taken into account in predictive models. (Fig.1 a) . The equivalent NTCPs after > 18 months follow-up (n=117) were 5.4% (95% CI: 1.0-11.5%), 15.9% (95% CI: 8.0-24.2%) and 36.0% (95% CI: 24.2-48.7%) (Fig.1b) .
Conclusions: This study helped to define the tolerance level of the thyroid gland by exploring a consecutive cohort of HNSCC patients treated primarily with IMRT and no surgery. Mean thyroid dose and low thyroid volume were significantly associated with biochemical HT. HT was observed after only a few months in this cohort. Doseresponse analysis showed a 12-15% risk of HT after 40 Gy, depending on observation time. 
